Repligen price target raised to $165 from $160 at Jefferies

Jefferies raised the firm’s price target on Repligen (RGEN) to $165 from $160 and keeps a Hold rating on the shares following a “solid 4Q showing,” FY25 guidance that was slightly ahead of expectations and “largely upbeat order commentary.” The firm still sees several of “outstanding questions, including what is baked in for new modalities and regarding the company’s plans for M&A, the analyst tells investors.